Background: Phenylketonuria (PKU) is a rare inborn error of metabolism that affects the
INTRODUCTION
Phenylketonuria (PKU, ORPHA79254, MIM 261600) is a genetic disorder that arises due to mutations in the gene that codes for phenylalanine hydroxylase (PAH; EC 1.14.16.1), a hepatic enzyme necessary for the metabolism of the essential amino acid phenylalanine (Phe) to tyrosine [1] . The resulting PAH deficiency leads to chronic increases in blood and tissue Phe concentrations, with toxic effects on the brain. PKU is an orphan disease with a mean prevalence in Europe of 1:10,000 [2] . If left untreated, it will lead to severe mental retardation, with additional symptoms such as autism, epilepsy and eczema. Since the 1960s, in most European countries, these severe complications can effectively be prevented by detection through newborn screening and early start of treatment, usually within the first two weeks of life [3] .
Treatment of PKU consists of a very strict and unpalatable diet that severely restricts intake of natural protein, with supplementation of other amino acids in a mixture with vitamins and minerals [2, 4] . Energy is provided by food that is naturally low in protein such as fruit and non-starchy vegetables, as well as specially formulated products such as pastas, breads, imitation cheese and baking mixes designed for low-protein diets [5] .
Some patients may benefit from treatment with BH4 (sapropterin), the cofactor of the PAH enzyme, which increases PAH activity and consequently lowers Phe blood concentrations in responsive PKU patients [6, 7] .
Disease severity can be classified by the Phe blood level at the time of diagnosis, or be based on the tolerance for the dietary intake of Phe during treatment. Several classifications are used in the literature; one of the common classifications describes patients as having classical PKU (untreated Phe level > 1000 μmol/L, Phe tolerance b 500 mg/day) or mild PKU (untreated Phe level ≤ 1000 μmol/L, Phe tolerance ≥ 500 mg/day) [2, 4, 8, 9] .
Even if treatment is started early, patients may suffer from executive deficits and mood disturbances. As these effects are strongly associated with concurrent Phe levels, a diet for life is usually advised [10] [11] [12] . Poor executive functions may lead to "hidden disabilities" such as difficulties in planning, organising and reduced processing speed, thereby affecting treatment adherence, social relationships, and job performance [13] .
~ 76 ~ Most studies report a normal health related quality and course of life in patients who are treated early and continuously, even though patients often report having certain restrictions with an evident lack of spontaneity in their lives [14] [15] [16] [17] . This reporting of "normal" health related quality of life (HRQoL) is probably due to the fact that the generic questionnaires available for measuring HRQoL do not evaluate specific PKU related problems. However, the authors are currently aware of a disease specific questionnaire being developed for PKU and this will hopefully provide more insight into the HRQoL of PKU patients.
The PKU diet is considered a heavy burden by both patients and professionals [18] and the management of PKU can be time consuming for both adult patients and caregivers of PKU-affected children. Patients and caregivers need to obtain low-protein food products, plan the daily Phe intake, prepare the daily menu (that often involves extra cooking), and prepare and take (or supervise the intake of) supplements. Furthermore, Phe intake has to be closely monitored with regular blood testing of Phe levels. The Dutch Guidelines recommend once weekly testing during the first year of life, twice monthly from age 1, monthly after age 4, and twice weekly during pregnancy if the mother has PKU [12] .
PKU may additionally present an economic burden to patients and caregivers. This includes direct costs of living with PKU, which relates to resource utilisation in managing their condition, such as low-protein foods, supplements, medications, laboratory monitoring, and healthcare visits. There may also be indirect costs such as those arising from the loss of productivity. Costs and reimbursement of diet therapy vary widely between different countries [19] . In the Netherlands patients with PKU and caregivers of PKU-affected children receive tax credits and amino acid supplements are reimbursed. Although information is available on the burden of PKU to the healthcare system [20] , there is not much information available on the personal time burden and cost of living with PKU for patients.
To gain insight into the personal time burden and cost of living with PKU in the Netherlands, we conducted a cross-sectional study that assessed the impact of PKU on adult patients and caregivers of PKU-affected children. Our aim was to measure the The Time Consuming Nature of PKU ~ 77 ~ time spent on activities related to PKU management and also to measure the out-ofpocket costs (OOPCs). The OOPC refers to those PKU-related expenses that are not reimbursed by the healthcare system. Any differences in OOPC and time burden according to different categories of patients (adult patients, caregivers, age, disease severity and adherence to diet) were also evaluated. Medical costs of PKU to the healthcare system are not considered in this study as the study focuses solely on the personal burden of PKU on affected individuals.
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METHODS
Study design and study population
We conducted a cross-sectional study to evaluate the costs and time burden of living with PKU in the Netherlands from the perspectives of the patient or the caregiver.
Different aspects of the PKU lifestyle that present any potential monetary costs were presented to participants in an internet-based questionnaire through which respondents could indicate their OOPCs and time spent on managing a PKU lifestyle. Patients were recruited from seven metabolic centres in the Netherlands. Early and continuously treated adult patients and caregivers of paediatric patients (who were already participating in another internet-based PKU study including patients age 4 years and older) were invited to participate in this study as well.
Development of the questionnaires
A systematic literature review was performed to identify all available data on costs associated directly with PKU and aspects of PKU that affect HRQoL. This was to gain insight into the PKU lifestyle that would facilitate preparing a script for expert interviews. The search was specific for costs borne by patients and their families rather than the healthcare system. This included the costs of treating the symptoms of PKU as well as any costs associated with managing the disease or looking after patients with PKU. Information was categorised into disease subgroups, such as severe versus mild; this was to enable assessment of how the burden of PKU varied for different patient characteristics. A second literature search was performed in order to obtain guidance in the creation of the questionnaire, including the identification of any suitable prevalidated questionnaires that captured information on productivity loss and healthcare resource use that could be incorporated into the survey. The findings of the literature reviews were confirmed through interviews with six opinion leaders in the field of PKU, three of whom were from the UK and three from the Netherlands, who detailed the various costs associated with the management of PKU. This ensured that all potential The questionnaires, which were created in English and then translated to Dutch, were reviewed by four experts. They were appraised at the Dutch National PKU event by four caregivers and one adult patient who were asked to provide feedback on their ease-ofunderstanding as well as any possible suggestions for further areas that may be covered.
The questionnaires were reviewed based on feedback obtained, with further input from two experts.
Data collection
Patients were recruited on an ongoing basis through the database of the Academic Medical Center (AMC), Amsterdam, from mid-December 2011 to early-April 2012.
Participants were sent two reminders over a three-month period to complete the questionnaire. Informed consent was obtained from all participants, and confidentiality was assured. Participation was voluntary and there were no implications on treatment for participants. Participants received a fee after completing the questionnaire, of which they were not informed prior to filling out the questionnaire. Patient data sets were coded and ethical approval was requested from the Ethical Committee of the AMC who deemed that their approval was not necessary for this study.
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Data analysis
In addition to the overall time burden and cost of living with PKU, demographic and disease data were used for creating subgroups to compare the time burden and financial cost of living for different categories of patients within each subgroup: adult patient versus caregiver; age; severity of disease; adult patient versus caregiver in combination with disease severity; and dietary adherence compared with dietary non-adherence.
Disease severity was defined according to the amount of natural protein (or Phe) allowed per day for an individual patient: patients who are allowed >10 g of natural protein (500 mg of Phe) per day were classified as 'mild'; patients who are allowed ≤10 g of natural protein (500 mg of Phe) per day were classified as 'severe'. For assessing adherence, patients were asked to provide the number of days in which they did not adhere to the diet over the preceding 100-day period; patients were regarded as showing good adherence if this totalled 30 days or fewer. Monetary costs for patients were reported as OOPCs.
The analyses were performed based on the available case principle, including only those patients for which the outcome and covariates are known. The total number included in the analyses will differ across parameter estimations. All outcomes were continuous outcomes (time and OOPC) and inferences were described in terms of medians, means, interquartile ranges and ranges. To test whether differences between subgroups were statistically significant (two sided p-value b0.05) the Wilcoxon Rank Tests for skewed outcome distributions were used.
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RESULTS
Patient characteristics
A total of 69 participants from another web based PKU study in the Netherlands were invited to participate in the study; of these, 22 adult PKU patients and 24 caregivers of 
Time burden of PKU
The primary components of the time burden of PKU are summarized in Table 1 
Out of pocket costs for PKU
The primary components of OOPCs for patients with PKU are summarized in 
Other findings
Six adult patients and 6 caregivers reported receiving tax credits towards PKU products.
Loss of productivity was reported by 3 adult patients; additionally 3 patients indicated that health affected their performance at work. Caregivers did not report any production loss, although 2 caregivers reported leaving their employment in order to care for a PKU child and 1 changed their employment because of PKU.
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DISCUSSION
This is the first study to investigate the time burden and costs resulting from having PKU or caring for a child with PKU.
The most important outcome of our study is the considerable time burden posed on patients and families with PKU. As presented earlier in the results, the median time burden associated with managing PKU was 527 h/year (1 h and 24 min/day) for caregivers and 175 h/year (30 min/day) for adult patients. Time was mostly spent on cooking and preparing meals specifically for a Phe-restricted diet, followed by monitoring protein intake. The significantly higher time burden for caregivers versus adult patients suggests that less time is required for PKU management as patients enter adulthood and begin caring for themselves. Also, this fits with the idea that many adult patients tend to somewhat relax their diet [21] . Furthermore, the higher time burden associated with severe versus mild PKU is to be expected as greater disease severity necessitates more stringent dietary control and PKU monitoring.
It needs to be discussed whether the time spent on PKU management will truly pose a burden on the lives of patients and caregivers. On regular household tasks the caregivers reported to spend a mean of 2 h and 3 min/day (median 52 min), which is comparable to the mean 2 h and 10 min spent on household tasks in the general population by a Dutch parent of a family with a youngest child age 6-12 [22] . Patients and caregivers were explicitly asked to report the extra time spent on PKU management. Our study showed that management of PKU poses a considerable additional time burden on adults (30 min/day) and caregivers (1 h and 24 min), which could have been spent more valuable when not having to deal with PKU. As such, the time spent on managing PKU could take away time from other daily activities. As few caretakers reported change of employment or production loss as a result of having a child with PKU, the extra time needed to manage PKU will probably be taken away from leisure time. The time burden for adult patients is significantly less than for the caregivers; however, as "hidden disabilities" such as difficulties in planning and organizing have been reported in patients with PKU, this time burden may affect their daily lives as well.
~ 86 ~ There is a lack of published information on the time burden for other metabolic diseases; therefore comparison to other metabolic disorders is not feasible. However, a US study on the burden of patients with diabetes mellitus type I, found that patients spent on average 28.3 min a day managing their condition [25] . Additionally they spent Although diabetes is not a metabolic disorder, the diabetes study can be used for comparison with this study as they both involve dietary restrictions and regulation, and close disease monitoring. However, comparison between the two studies should be interpreted with caution as the activities that contributed to the time burden were different in each of the two studies; furthermore, the diabetes study reported mean values instead of median values as reported in the present study.
The median OOPC per patient (€604 annually) was comparable for both patients and caregivers. These costs were mainly due to expenditure on low-protein food products and for a small part on costs related to PKU testing equipment, postage of Phe blood tests, taking extra luggage on holiday to accommodate PKU equipment and attending PKU events. It can be easily explained that OOPCs are higher for patients with severe PKU than for those with mild PKU by the fact that greater disease severity necessitates more stringent protein restriction with a higher intake of low-protein food products. An important point to consider is whether these additional PKU-related costs are offset by the potentially cheaper natural diet imposed upon PKU patients that contains very little or no regular bread, dairy products or meat. In comparison to the general population: a Dutch adult on a normal diet has been demonstrated to spend a mean amount of €1200
annually on meat, cheese, milk, yoghurt and bread [26] . For patients with PKU this ~ 87 ~ expenditure is replaced by the costs of the low protein products. It may be expected that costs between protein containing and low protein food products will balance out in patients depending on disease severity and the need for low protein food products.
Taking this into account, it is unlikely that there will be a large burden of extra OOPCs for families of patients with PKU.
It must be stressed, however, that the costs of the Phe free protein supplements in a mixture with vitamins and minerals, which are an essential part of the diet of patients with PKU, vary per country but may be as high as €30,000 annually [19] . In most European countries these costs are reimbursed by the government, or as is the case in the Netherlands, by health insurance. To guarantee proper dietary treatment of patients with PKU and to avoid a disproportionate financial burden for patients and families, it is essential that costs of the Phe free protein supplements are reimbursed in all countries.
A limitation of our study was the low sample size, especially when results were analysed within subgroups. However, this is a consequence of the rarity of this disease, with approximately 550 earlytreated PKU patients in the Netherlands at present, a true orphan disease. Another limitation was the age limit used in our study. Since our questionnaire was joined on to an existing registry, patients aged 0-4 years were excluded. Furthermore, many participants were unwilling to reveal certain details such as their income, so it was not possible to formally analyse the impact of the cost of living on these patients according to their socio-economic status. Nevertheless, the main objective of the study to gain insight into the time burden and cost of living with PKU overall (rather than comparison between patient subgroups) was achieved.
CONCLUSIONS
With an extra daily time burden of 1 h and 24 min/day for caregivers of children with PKU and 30 min/day for adult patients, PKU management is highly time consuming. As was expected, the time burden was significantly higher for severe versus mild patients.
For both the caregivers and the adult patients the OOPC mainly consisted of the cost related to low protein foods.
